MedKoo Cat#: 574705 | Name: Galanthamine N-Oxide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Galanthamine N-Oxide is a metabolite of Galanthamine -- a selective acetylcholinesterase inhibitor.

Chemical Structure

Galanthamine N-Oxide
Galanthamine N-Oxide
CAS#134332-50-6

Theoretical Analysis

MedKoo Cat#: 574705

Name: Galanthamine N-Oxide

CAS#: 134332-50-6

Chemical Formula: C17H21NO4

Exact Mass: 303.1471

Molecular Weight: 303.36

Elemental Analysis: C, 67.31; H, 6.98; N, 4.62; O, 21.10

Price and Availability

Size Price Availability Quantity
1mg USD 350.00 2 Weeks
5mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Galanthamine N-Oxide; Galantamine N-Oxide; Galanthamine-N-oxide; Galanthamine 10-Oxide; Galanthamine β-N-oxide
IUPAC/Chemical Name
(4aS,6R,8aS,11R)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol 11-Oxide
InChi Key
LROQBKNDGTWXET-CSBKYJRVSA-N
InChi Code
InChI=1S/C17H21NO4/c1-18(20)8-7-17-6-5-12(19)9-14(17)22-16-13(21-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-,18+/m0/s1
SMILES Code
O[C@H]1C=C[C@@]23CC[N@@+](C)([O-])CC4=CC=C(OC)C(O[C@@]3([H])C1)=C24
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 303.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule M, Shoyele SA, Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018 May 14. pii: S0168-3659(18)30268-2. doi: 10.1016/j.jconrel.2018.05.011. [Epub ahead of print] Review. PubMed PMID: 29772289. 2: Hsu WY, Lane HY, Lin CH. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. Front Psychiatry. 2018 Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection 2018. Review. PubMed PMID: 29670547; PubMed Central PMCID: PMC5893641. 3: Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000207. doi: 10.1002/14651858.CD000207.pub2. Review. PubMed PMID: 29553158.